VioQuest Pharmaceuticals
VioQuest Pharmaceuticals' VQD-002 Named One of 10 Most Promising Oncology Projects by Windhover
Published in Cardiovascular Business Week, August 19th, 2008
VioQuest Pharmaceuticals (OTCBB: VOQP) announced that the company's novel Akt inhibitor VQD-002 (triciribine phosphate monohydrate, or TCN-P) has been selected as one of the Top 10 most promising oncology projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committee considered the most attractive cardiovascular opportunities the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Abiomed, Inc.
Abiomed Announces Impella 2.5 Capacity Expansion Plans in Ireland - Acorda Therapeutics
Acorda Therapeutics Presents Positive Data from Preclinical Studies of Neuregulins in Cardiac Function - Alcoholism
Alcohol Consumption Declining, According to Results of New Study - Alkermes, Inc.
Alkermes Announces Approval of VIVITROL for the Treatment of Alcohol Dependence in Russia - Angioplasty
Virtua Cardiologists Respond to Commentary on Angioplasty - Arrhythmia
Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
